Wire · opportunities
Korea pivots gout care as excretion drugs challenge production blockers
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 August 2026 · Fusion42 review
Korean pharmaceutical firms, led by JW Pharmaceutical, are shifting gout treatment from uric acid production inhibitors to new drugs promoting uric acid excretion, highlighted by the successful global phase 3 trials of Epaminurad. This represents a notable innovation in Korea's gout drug market with potential changes in treatment standards and regulatory approvals expected soon.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a new market opening as Korean regulators prepare to approve uric acid excretion drugs like Epaminurad. Your immediate move is to position your pipeline around these newer mechanisms or risk losing ground in gout treatment innovation.
◆ Coverage
1 source · 17 Aug 2026
◆ Related on Wire
◆ Topics